The United States Patent and Trademark Office (USPTO) has granted patent US12582709B2, titled 'Persistent memory T-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways.' The patent, assigned to The Regents of the University of California, details recombinant polynucleotides designed to encode antigens and enzymes of amino acid catabolic pathways, aiming to induce immune responses with improved memory characteristics. It also covers related pharmaceutical compositions, viral particles, and host cells.

This patent grant is primarily of informational value to entities in the biotechnology and pharmaceutical sectors involved in cancer and infectious disease research. While it does not impose new regulatory obligations, it signifies intellectual property protection for specific technologies related to immunotherapy. Companies operating in this space should be aware of this granted patent as it may impact their freedom to operate or potential licensing opportunities.